| Literature DB >> 28765744 |
Ji Seok Bang1,2, Gi Beom Kim1, Bo Sang Kwon1, Mi Kyung Song1, Hyo Soon An3, Young Whan Song4, Eun Jung Bae1, Chung Il Noh1.
Abstract
BACKGROUND AND OBJECTIVES: Some patients with Kawasaki disease (KD) develop large coronary aneurysms and subsequent coronary stenosis or obstruction, leading to ischemic heart disease. This study examined the long-term outcomes of patients with KD complicated by large coronary aneurysms. SUBJECTS AND METHODS: The medical records of 71 patients (53 men and 18 women) diagnosed with large coronary aneurysms (diameter ≥6 mm) between December 1986 and December 2013 were retrospectively reviewed from our institutional database.Entities:
Keywords: Coronary aneurysm; Mucocutaneous lymph node syndrome; Myocardial infarction; Prognosis
Year: 2017 PMID: 28765744 PMCID: PMC5537154 DOI: 10.4070/kcj.2016.0163
Source DB: PubMed Journal: Korean Circ J ISSN: 1738-5520 Impact factor: 3.243
Baseline characteristics of patients with large coronary artery aneurysm (≥6 mm)
| Characteristics | Values |
|---|---|
| Male:female | 53:18 (74.6:25.4) |
| KD criteria | |
| Complete | 46 (64.7) |
| Incomplete | 5 (7.0) |
| Unknown | 20 (28.3) |
| Primary admission: referred patients | 10:61 (14:86) |
| Age at the onset of KD* | 4.6±3.3 years (range: 0.3-14 years) |
| Follow-up duration | Median 11.3 years (range: 0.2-27.6 years) |
| Fever duration with/without IVIG therapy | 13.0±6.5 days (range: 4.0-40 days) |
| Interval between CA diagnosis and KD onset | 22.9±15.2 days (range: 2.0-69.0 days) |
| The maximum CA internal diameter | Median 9 mm (range: 6.1-25 mm) |
| Recurrence rates | 4/71 (5.6) |
| Treatment with IVIG | 67/71 (94.3) |
| IVIG infusion day since fever onset | 7.6±4.6 days (range: 3-22 days) |
| IVIG total dose | |
| ≤2 g/kg | 24 (33.8) |
| 2-4 g/kg | 11 (15.5) |
| 4-6 g/kg | 8 (11.3) |
| 6-8 g/kg | 1 (1.4) |
| Unknown | 27 (38) |
| Steroid therapy | 13 (18.3) |
| Other therapy | 1 methotrexate, 2 infliximab |
| Long-term antithrombotic agents | |
| Aspirin, dipyridamole | 21 (29.6) |
| Aspirin | 19 (26.7) |
| Aspirin, clopidogrel | 14 (19.7) |
| Aspirin, warfarin | 10 (14.1) |
| Aspirin, dipyridamole, warfarin | 2 (2.8) |
| Aspirin, clopidogrel, warfarin | 2 (2.8) |
| Dipyridamole | 1 (1.4) |
| Dipyridamole, warfarin | 1 (1.4) |
| Warfarin | 1 (1.4) |
Values are presented as mean±standard deviation or number (%). *Five adult patients were excluded. KD: Kawasaki disease, CA: coronary aneurysm, IVIG: intravenous immunoglobulin
Comparison of clinical features of the CA size 6-8 mm vs. ≥8 mm groups
| Group I (n=23) | Group II (n=48) | p | |
|---|---|---|---|
| CA size (mm) | 6.9±0.6 | 10.7±3.5 | 0.903 |
| Fever duration (days) | 14.6±8.1 | 12.0±5.8 | 0.098 |
| CA stenosis or occlusion | 7 (30.4) | 27 (56.3) | 0.106 |
| Intervention (PCI or CABG) | 4 (17.3) | 20 (41.7) | 0.148 |
| Myocardial infarction | 0 (0) | 7 (14.6) | <0.001 |
Values are presented as mean±standard deviation or number (%). Group I: the internal diameter of coronary artery 6-8 mm, Group II: the internal diameter of coronary artery ≥8 mm. CA: coronary aneurysm, PCI: percutaneous coronary intervention, CABG: coronary artery bypass graft surgery
Fig. 1Kaplan-Meier actuarial freedom from cardiac events. (A) Freedom from any intervention between coronary aneurysm size (6-8 mm vs. ≥8 mm). Trans-catheter and/or surgical coronary interventions were performed in 20 patients, resulting in a 33.7% cumulative coronary intervention rate at 20 years after KD onset. There were no differences in cumulative coronary intervention rates between two coronary aneurysm groups (p=0.148). (B) Freedom from myocardial infarction. The median elapsed time from KD onset to myocardial infarction was 3.0 months (range: 0.5-31.2 months). Cumulative survival rate was 89.6% and most myocardial infarction occurred in the first year after onset of giant coronary aneurysm. KD: Kawasaki disease.
Clinical data in patients with myocardial infarction
| No. | Age at KD onset (years) | Sex | Time interval from onset to MI (months) | Largest size of aneurysm | Medicationsbefore MI | Lesion of coronary artery | Treatment | Prognosis |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.2 | M | 1.5 | 15.0 | Warfarin, dipyridamole | RCA occlusion | PCI | Alive |
| 2 | 4.6 | M | 31.2 | 8.0 | Warfarin, aspirin | LMCA thrombus | PCI | Alive |
| 3 | 6.3 | M | 4.0 | 12.0 | Warfarin, aspirin | LAD, RCA occlusion | CABG | Alive |
| 4 | 2.0 | M | 30.0 | 8.3 | Warfarin, aspirin | LAD, LCX occlusion | PCI | Death |
| 5 | 8.2 | M | 8.0 | 10.8 | Aspirin, clopidogrel | RCA occlusion | PCI | Alive |
| 6 | 2.5 | F | 0.5 | 13.6 | Aspirin | RCA thrombus | PCI | Alive |
| 7 | 5.2 | M | 2.0 | 23.0 | Warfarin, aspirin | LAD, RCA thrombus | PCI | Alive |
KD: Kawasaki disease, RCA: right coronary artery, LMCA: left main coronary artery, LAD: left anterior descending artery, LCX: left circumflex artery, MI: myocardial infarct, PCI: percutaneous coronary intervention, CABG: coronary artery bypass graft